Novartis AG (NVS)

79.13
2.60 3.10
NYSE : Health Technology
Prev Close 81.70
Open 79.76
Day Low/High 78.81 / 79.82
52 Wk Low/High 72.67 / 94.19
Volume 5.44M
Avg Volume 1.67M
Exchange NYSE
Shares Outstanding 2.63B
Market Cap 212.13B
EPS 3.30
P/E Ratio 24.93
Div & Yield 2.52 (3.11%)

Latest News

Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets

Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets

Ultragenyx scored its second FDA drug approval in six months. The orphan disease specialist also picked up its second Rare Pediatric Disease Priority Review Voucher; its first sold for $130 million.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discuss the FAANG stocks, a market bottom, and potential biotech targets.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

We Got Too Negative: Cramer's 'Mad Money' Recap (Monday 4/9/18)

We Got Too Negative: Cramer's 'Mad Money' Recap (Monday 4/9/18)

Jim Cramer says we're seeing powerful reminders that there's a better time to sell than in the teeth of a decline. Investors must use discipline to their advantage.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks rise Monday following tweets from Donald Trump that appeared to indicate the U.S. was softening its approach in its trade battle with China.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces

Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces

Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Markets around the globe last week were tumultuous after both China and the U.S. proposed tariffs on imported goods as investors weigh whether the countries will come to the table to negotiate an end to the spat.

5 Thing You Must Know Before Monday's Opening Bell

5 Thing You Must Know Before Monday's Opening Bell

U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.

Novartis Agrees to Buy AveXis in $8.7 Billion Deal

Novartis Agrees to Buy AveXis in $8.7 Billion Deal

The acquisition is a big move for Novartis CEO Vas Narasimhan, who took the helm in February.

Blackberry, SkyWest, Apache: 'Mad Money' Lightning Round

Blackberry, SkyWest, Apache: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Blackberry, SkyWest, Apache, Philip Morris International, PetMed Express, Iron Mountain, Novartis.

Behind the Selloff: Cramer's 'Mad Money' Recap (Friday 4/6/18)

Behind the Selloff: Cramer's 'Mad Money' Recap (Friday 4/6/18)

This market is deceptive and you need to recognize your sense of timing is not infallible. So, adjust your scales and get ready for next week, says Jim Cramer.

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

M&A activity kicks into high gear going into the final days of the first quarter. If the broader stock market doesn't pop on this news, it would be a red flag.

IIROC Trading Halt - NVS

IIROC Trading Halt - NVS

The Dow Plunges Into the Close of Trading on Tuesday

The Dow Plunges Into the Close of Trading on Tuesday

Cooling tensions with China aren't enough to save investors on Tuesday.

Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday

Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday

With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.

Facebook, Novartis, GSK, Uber and Deutsche Bank - 5 Things You Must Know

Facebook, Novartis, GSK, Uber and Deutsche Bank - 5 Things You Must Know

U.S. stock futures rise and global stocks extend their rally; Novartis to sell 36.5% stake in joint venture to partner GSK for $13 billion; Facebook's Mark Zuckerberg won't face U.K. lawmakers.

Global Stocks Ride Wall Street Wave as U.S.-China Trade Talks Tempt Bulls

Global Stocks Ride Wall Street Wave as U.S.-China Trade Talks Tempt Bulls

Wall Street's best day in nearly three years has global stocks on the move Tuesday, with U.S.-China trade talks and a wave of late quarter M&A boosting markets around the world.

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Here's what you need to know now for Tuesday, March 6.

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.

IIROC Trade Resumption - NVS

IIROC Trade Resumption - NVS

TheStreet Quant Rating: B- (Buy)